Navigation Links
Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
Date:3/11/2009

A CCR5 Antagonist That is Dosed Once Daily Could Earn an 18 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed infectious disease specialists identify a therapy's effect on the ability to achieve viral load suppression in treatment-naive patients as the attribute that most influences their prescribing decisions in HIV. Surveyed specialists indicate they are highly satisfied with Gilead/Bristol Myers Squibb's Atripla and Merck's Isentress in this attribute.

The new report entitled HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists finds that a novel drug in the CCR5 antagonist class that is dosed once daily and achieves maximum physician expectations would earn an 18 percent patient share in HIV in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European infectious disease specialists.

In 2008, Decision Resources' proprietary clinical gold standard for HIV was Merck's Isentress/Gilead's Truvada. Based on expert opinion, Isentress/Truvada will retain clinical gold standard status through 2017, owing to its balance of efficacy, novel mechanisms of action and safety. Although some therapies in development for HIV hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed thought leaders believe are inferior when compared with Isentress/Truvada.

"Experts we surveyed rated Isentress plus Truvada as one of the safest antiretroviral regimens available," said Decision Resources Analyst Jose Avalos, Ph.D. "Furthermore, interviewed specialists believe Isentress' novel mechanism of action provides advantages in highly treatment experienced patients."

About the Report

HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563
    ccomfort@dresources.com                       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. For Primary Care, More Patients Are Seeing Specialists
2. Specialists On Call Earns the Hospital Association of Southern Californias Endorsement
3. Specialists On Call Expands Access to Emergency Neurology On-Call Services in Montana
4. Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Virginia
5. Wound Care Certification Course Endorsed by the American College of Certified Wound Specialists
6. Specialists On Call Expands Senior Management & Sales Teams
7. Texas Health Dallas New Intensivist Program Puts Critical-Care Specialists in the ICU - All the Time
8. Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Texas
9. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
10. Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions
11. Medical Specialists of the Palm Beaches Selects Allscripts Electronic Health Record to Connect and Automate 85 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... 28, 2017 , ... The Military Family Initiative (MFI), a ... the grant recipients of its inaugural community outreach grant program. , MOAA ... Falcon’s Landing Chapter, Sterling, Va.: $5,000. Community Veterans Collaboration. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... Stephen Weber, MD, is excited to ... science of Platelet Rich Plasma (PRP). Founder of Weber Facial Plastic Surgery, Dr. Weber’s ... women. Through his groundbreaking PRP procedures, Dr. Weber is quickly bringing hair loss treatment ...
(Date:7/28/2017)... , ... July 28, 2017 , ... ActivePDF, a global ... Best Places to Work in Orange County. As a multi-year recipient, ActivePDF continues to ... County, CA. , ActivePDF is known for their code-driven suite of PDF automation products, ...
(Date:7/28/2017)... ... July 28, 2017 , ... At its first ginger symposium on July 18, ... ginger industry. The funds will be used for land preparation, seed and organic farming ... budget will support both new and existing small-hold farmers and will also help strengthen ...
(Date:7/28/2017)... ... July 28, 2017 , ... Date aired: July 17th, 2017 , Guest: ... of first generation immigrants before her, Rose Hong came to America to realize a ... the part of loving parents who made sure their daughter got to the U.S. ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... Minn. , July 20, 2017  Prime Therapeutics LLC ... Jonathan Gavras , M.D., following today,s Institute for Clinical and ... report on the effectiveness and value of abuse-deterrent formulations ... on the policy roundtable at the meeting. ... not a material cost benefit to the use of abuse-deterrent ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
Breaking Medicine Technology: